Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.

The U.S. Food and Drug Administration banned Red No. 3 last dye, leading those to think Red Dye No. 40 could be next. How are ...

Adding a monoclonal antibody cocktail to the standard treatment for inoperable liver cancer nearly doubled the amount of time ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.

Discover which popular foods will be affected by the FDA's new ban on Red No. 3, the synthetic dye that adds a vibrant pop of ...

Meanwhile, the HHS website scrubbed search results for the word "abortion," and ReproductiveRights.gov -- a site the Biden ...

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...

Researchers reporting in ACS Central Science have created a novel treatment that eliminated small breast tumors and ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...